{
    "nctId": "NCT05263570",
    "briefTitle": "The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.",
    "officialTitle": "The Efficiency for Patient With Stage II-III HR+/HER2+ Early Breast Cancer With Standard Neoadjuvant Therapy: a Retrospective, Multicenter Study in Real World Settings.",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Total pathological complete response (tpCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u226518 years or older\n* HR+/HER2- breast cancer diagnosis based on local standards\n* Women having stage II-III breast cancer diagnosed based on AJCC cancer staging system (8th edition) who will be admitted because of breast cancer for the first time\n* Standard Therapy, determined at the discretion of the investigator, including \uff08TCbHP/THP/EC-THP/AC-THP\uff09\n* Complete medical history was available\n* Karnofsky Performance Status (KPS) Scale score \u2265 70\n\nExclusion Criteria:\n\n* Women who have received any form of anti-tumor treatment - (chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy)\n* Pregnant or breast-feeding women\n* Those who have bilateral breast cancer, inflammatory breast cancer or occult breast cancer\n* Those who have stage IV breast cancer",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}